Navigation Links
John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting
Date:7/18/2011

HACKENSACK, N.J. (July 18, 2011) Researchers from the John Theurer Cancer Center at Hackensack University Medical Center presented results from 14 cancer-related studies during the recently concluded American Society of Clinical Oncology (ASCO) Annual Meeting, which took place June 3 7, 2011 in Chicago. The studies examined new cancer treatments, ways to predict the best treatment outcomes, and patient quality of life issues.

"ASCO is a great venue for sharing best practices and learning about new treatment approaches we are proud to help contribute by presenting our recent scientific work," said Andre Goy, M.D., M.S., Chairman and Director and Chief of Lymphoma, John Theurer Cancer Center. "Our researchers will keep working to improve oncology and help develop some of the newest approaches to treating cancer. This will remain a priority for our cancer center."

Among other promising research, John Theurer Cancer Center investigators reported on a phase II study of carfilzomib, a new proteasome inhibitor to treat advanced multiple myeloma; the first phase III trial of anti-metabolite clofarabine against acute myelogenous leukemia; application of a new statistical model to predict mantle cell lymphoma survival and guide treatment choices; and a comparison of disease status and satisfaction with care among chronic myeloid leukemia patients.

"The innovative research we conduct brings tomorrow's treatments to our patients today," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., Chief Innovations Officer and Professor and Vice President of Cancer Services, John Theurer Cancer Center. "We have recently expanded our capabilities through the opening of an extraordinary new research and patient care facility, and it is our belief that this will enable us to further speed the pace of discovery and be even more prolific in our scientific publications."

Highlights of the Theurer Center presentations include:

PX-171-003-A1, an o
'/>"/>

Contact: Amy Leahing
Amy.leahing@zibbel.com
John Theurer Cancer Center
Source:Eurekalert

Page: 1 2 3 4 5 6

Related biology news :

1. John Theurer Cancer Center BMT researchers highlight the importance of social support
2. Cancer stem cells recruit normal stem cells to fuel ovarian cancer, U-M study finds
3. Trastuzumab and chemotherapy improved survival in HER2-postive breast and brain cancer patients
4. UT Southwestern research reveals that significantly more genetic mutations lead to colon cancer
5. Cancer gene therapy from camels
6. Cancer data not readily available for future research
7. UT faculty improving surgical outcomes for children, cancer patients
8. Study explains why men are at higher risk for stomach cancer
9. Stem cells restore cognitive abilities impaired by brain cancer treatment
10. PSA test for men could get a second life for breast cancer in women
11. Low dose naltrexone (LDN): Harnessing the bodys own chemistry to treat human ovarian cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... for its School of Medicine. Funding for this $50 ... campaign that will be publicly launched next summer. ... in the former 60 series R.J. Reynolds Tobacco Company ... Construction will begin immediately with plans to be ready ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
(Date:12/5/2014)... 2014 Increased emphasis on product quality, ... testing and inspection technologies. The convergence of industries ... range of innovative test solutions. This trend is ... which is generally more inclined towards communication, media ... strategies of test equipment vendors will cater to ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... of the American Medical Society ("Medical News & ... Associate Professor Sergei Adamovich, a biomedical engineer. Adamovich and ... and Eugene Tunik, PhD, PT, at the University of ... robotic and virtual reality-based video game therapies to help ...
... that the animal with the most genes--about 31,000--is the ... By comparison, humans have about 23,000 genes. Daphnia is ... The water flea,s genome is described in a ... the Daphnia Genomics Consortium, an international network of scientists ...
... provided the first conclusive evidence that cannabis use significantly hastens ... brain development with possible life-long consequences. The ... smoking cannabis is associated with an earlier onset of psychotic ... an international team including Dr Matthew Large, from the University ...
Cached Biology News:JAMA features NJIT biomedical engineer helping stroke patients 2JAMA features NJIT biomedical engineer helping stroke patients 3The most genes in an animal? Tiny crustacean holds the record 2The most genes in an animal? Tiny crustacean holds the record 3Cannabis linked to earlier onset of psychosis 2
(Date:12/24/2014)... 24, 2014  Vermillion, Inc. (Nasdaq:   VRML), ... announced today that the Company closed its previously ... Management, Jack W. Schuler , Birchview Fund ... $10.5 million, before offering expenses.  The proceeds will ... purposes. Under the terms of the ...
(Date:12/24/2014)... December 23, 2014 ... is designed to introduce cutting edge communication ... and partners of platform upgrades. This webinar ... empowering users in their quest to leverage ... , According to SoundConnect’s Marketing Manager, Seanna ...
(Date:12/24/2014)... The report expects global cell isolation and expansion ... provides a carefully analyzed data about the vital drivers, ... , Full Copy of Report @ http://bit.ly/1yUxy0T ... cell expansion will keep witnessing growth at an impressive ... be driven by rapid technological advancements, government funding and ...
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich ... that the waiting period under the Hart-Scott-Rodino Antitrust ... acquisition expired on December 22, 2014, thereby completing ... requirement for the acquisition of the Company by ... antitrust clearance satisfies another condition to closing the ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3
... NOVATO, Calif., Sept. 8 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... present a company update at the Morgan Stanley Healthcare Conference in New ... , , Interested parties may access a live ... BioMarin website, www.BMRN.com . A replay of the ...
... , NEW BRUNSWICK, N.J., Sept. 8 ... SNT ) today announced that the Company will be presenting at ... held at the New York Palace Hotel from September 9th - ... will deliver the Company,s corporate presentation on Friday, September 11th, at ...
... CAMBRIDGE, Massachusetts, September 8 Shire plc,(LSE: SHP, ... company, is,committed to doing everything possible to assist Gaucher ... is pleased to be,able to provide velaglucerase alfa well ... wide. , In the U.S., ...
Cached Biology Technology:BioMarin to Present at the Morgan Stanley Healthcare Conference 2Senesco Technologies to Present at 11th Annual Rodman & Renshaw Healthcare Conference 2Update on velaglucerase alfa 2Update on velaglucerase alfa 3
Goat polyclonal to NIR1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: SWARGPPKFESVP, corresponding to C terminal amino acids 962-974 of NIR1. Entrez Gene ID: 83394 ...
HOXC11 Antibody...
Anti-MMP-14, catalytic domain, clone LEM-2/15.8 Immunogen: Synthetic peptide: amino acid sequence 218-233 within the catalytic domain Available Date: 38579...
Anti-MMP-19 (RASI), carboxy terminal region; rabbit host...
Biology Products: